NaokiKashihara Japan

Time	Session

08:10 09:10	Industry Symposium 5 HiddoLambers Heerspink Moderator h.j.lambers.heerspink@umcg.nlNetherlands NaokiKashihara Moderator kashinao@med.kawasaki-m.ac.jpJapan Clinical Impacts and Importance of Minimizing Drug Approval Delay NaokiKashihara Speaker kashinao@med.kawasaki-m.ac.jpJapan HCE (hierarchical composite end points) and eGFR slope, as potential solutions to delays in approval HiddoLambers Heerspink Speaker h.j.lambers.heerspink@umcg.nlNetherlands Bridging Academia and Regulators in Kidney Drug Development: Insights from Japan MototsuguTanaka Speaker Japan Panel Discussion DustinLittle Moderator United States HiddoLambers Heerspink Speaker h.j.lambers.heerspink@umcg.nlNetherlands MototsuguTanaka Speaker Japan NaokiKashihara Speaker kashinao@med.kawasaki-m.ac.jpJapan 301 - 302
12:50 13:50	Industry Symposium 13 KeiFukami Moderator Japan The Importance of Guideline Directed Therapy Christoph Wanner Speaker wanner_c@ukw.deGermany Long-term Management of Hyperkalemia with Safety NaokiKashihara Speaker kashinao@med.kawasaki-m.ac.jpJapan 315
17:00 18:00	Industry Symposium 30 YOSHITAKAISAKA Moderator Japan Transformative Insights from the DAPA-CKD Trial: Lessons for the Future of Kidney Care NaokiKashihara Speaker kashinao@med.kawasaki-m.ac.jpJapan 501 - 502